Hugel’s main focus for 2022 is to go global, with the goal of claiming 10 percent of the world market share for botulinum toxin in five years.
Bain Capital has sold its 42.9-percent stake plus convertible bonds in Kosdaq-listed Hugel, Korea's largest manufacturer of botulinum toxin.
Korea JoongAng Daily Sitemap
